CXCL10 May Be Responsible for Susceptibility to Pulmonary Embolism in COVID-19 Patients

References

• Yuan Y, Jiao B, Qu L, et al. The development of COVID-19 treatment. Front Immunol. 2023;14:1125246. doi:10.3389/fimmu.2023.1125246
   PubMedGoogle Scholar
• Zhang JJ, Dong X, Liu GH, et al. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2023;64(1):90–107. doi:10.1007/s12016-022-08921-5
   PubMed Web of Science ®Google Scholar
• Dou Q, Wei X, Zhou K, et al. Cardiovascular manifestations and mechanisms in patients with COVID-19. Trends Endocrinol Metab. 2020;31(12):893–904. doi:10.1016/j.tem.2020.10.001
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C. Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach. Eur Respir J. 2015;45(4):1142–1149. doi:10.1183/09031936.00164714
   PubMed Web of Science ®Google Scholar
• Essien EO, Rali P, Mathai SC. Pulmonary Embolism. Med Clin North Am. 2019;103(3):549–564. doi:10.1016/j.mcna.2018.12.013
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. doi:10.1093/eurheartj/ehz405
   PubMed Web of Science ®Google Scholar
• Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142(2):184–186. doi:10.1161/CIRCULATIONAHA.120.047430
   PubMed Web of Science ®Google Scholar
• Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098. doi:10.1007/s00134-020-06062-x
   PubMed Web of Science ®Google Scholar
• Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9(3):251–259. doi:10.1016/S2213-2600(20)30527-0
   PubMed Web of Science ®Google Scholar
• Suh YJ, Hong H, Ohana M, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2021;298(2):E70–E80. doi:10.1148/radiol.2020203557
   PubMed Web of Science ®Google Scholar
• Zuin M, Engelen MM, Bilato C, et al. Prevalence of acute pulmonary embolism at autopsy in patients with COVID-19. Am J Cardiol. 2022;171:159–164. doi:10.1016/j.amjcard.2022.01.051
   PubMed Web of Science ®Google Scholar
• Katsoularis I, Fonseca-Rodriguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377:e069590. doi:10.1136/bmj-2021-069590
   PubMedGoogle Scholar
• Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a Prospective Cohort Study. Ann Intern Med. 2020;173(4):268–277. doi:10.7326/M20-2003
   PubMed Web of Science ®Google Scholar
• Safiriyu I, Fatuyi M, Mehta A, et al. Impact of COVID-19 infection on the clinical outcomes of pulmonary embolism hospitalizations: a nationwide analysis. Curr Probl Cardiol. 2023;48(7):101669. doi:10.1016/j.cpcardiol.2023.101669
   PubMed Web of Science ®Google Scholar
• Tadlock MD, Chouliaras K, Kennedy M, et al. The origin of fatal pulmonary emboli: a postmortem analysis of 500 deaths from pulmonary embolism in trauma, surgical, and medical patients. Am J Surg. 2015;209(6):959–968. doi:10.1016/j.amjsurg.2014.09.027
   PubMed Web of Science ®Google Scholar
• Ahuja J, Shroff GS, Benveniste MF, et al. In situ pulmonary artery thrombosis: unrecognized complication of radiation therapy. AJR Am J Roentgenol. 2020;215(6):1329–1334. doi:10.2214/AJR.19.22741
   PubMed Web of Science ®Google Scholar
• Cao Y, Geng C, Li Y, et al. In situ pulmonary artery thrombosis: a previously overlooked disease. Front Pharmacol. 2021;12:671589. doi:10.3389/fphar.2021.671589
   PubMed Web of Science ®Google Scholar
• Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–128. doi:10.1056/NEJMoa2015432
   PubMed Web of Science ®Google Scholar
• Poor HD. Pulmonary thrombosis and thromboembolism in COVID-19. Chest. 2021;160(4):1471–1480. doi:10.1016/j.chest.2021.06.016
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Sonaglia A, Casarotto L, et al. Clinical, laboratory and immunohistochemical characterization of in situ pulmonary arterial thrombosis in fatal COVID-19. Thromb Res. 2022;219:95–101. doi:10.1016/j.thromres.2022.09.012
   PubMed Web of Science ®Google Scholar
• Fauvel C, Weizman O, Trimaille A, et al. Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. Eur Heart J. 2020;41(32):3058–3068. doi:10.1093/eurheartj/ehaa500
   PubMed Web of Science ®Google Scholar
• Bompard F, Monnier H, Saab I, et al. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J. 2020;56(1). doi:10.1183/13993003.01365-2020
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen C, Chen F, et al. Bioinformatics analysis of potential pathogenesis and risk genes of immunoinflammation-promoted renal injury in severe COVID-19. Front Immunol. 2022;13:950076. doi:10.3389/fimmu.2022.950076
   PubMed Web of Science ®Google Scholar
• Li Y, Liu Y, Duo M, et al. Bioinformatic analysis and preliminary validation of potential therapeutic targets for COVID-19 infection in asthma patients. Cell Commun Signal. 2022;20(1):201. doi:10.1186/s12964-022-01010-2
   PubMed Web of Science ®Google Scholar
• Lv Y, Zhang T, Cai J, et al. Bioinformatics and systems biology approach to identify the pathogenetic link of Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Front Immunol. 2022;13:952987. doi:10.3389/fimmu.2022.952987
   PubMed Web of Science ®Google Scholar
• Zhang W, Di L, Liu Z, et al. TIMELESS is a key gene mediating thrombogenesis in COVID-19 and antiphospholipid syndrome. Sci Rep. 2022;12(1):17248. doi:10.1038/s41598-022-21694-3
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259. doi:10.1007/978-1-4939-7493-1_12
   PubMedGoogle Scholar
• Shen W, Song Z, Zhong X, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022;1(3):e36. doi:10.1002/imt2.36
   Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Ramasamy S, Subbian S. Critical determinants of cytokine storm and Type I interferon response in COVID-19 pathogenesis. Clin Microbiol Rev. 2021;34(3). doi:10.1128/CMR.00299-20
   Web of Science ®Google Scholar
• Coperchini F, Chiovato L, Ricci G, et al. The cytokine storm in COVID-19: further advances in our understanding the role of specific chemokines involved. Cytokine Growth Factor Rev. 2021;58:82–91. doi:10.1016/j.cytogfr.2020.12.005
   PubMed Web of Science ®Google Scholar
• Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, et al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75. doi:10.1016/j.cytogfr.2020.06.001
   PubMed Web of Science ®Google Scholar
• Hsu RJ, Yu WC, Peng GR, et al. The role of cytokines and chemokines in severe acute respiratory syndrome Coronavirus 2 infections. Front Immunol. 2022;13:832394. doi:10.3389/fimmu.2022.832394
   PubMed Web of Science ®Google Scholar
• Wang S, Yao X, Ma S, et al. A single-cell transcriptomic landscape of the lungs of patients with COVID-19. Nat Cell Biol. 2021;23(12):1314–1328. doi:10.1038/s41556-021-00796-6
   PubMed Web of Science ®Google Scholar
• Khismatullin RR, Ponomareva AA, Nagaswami C, et al. Pathology of lung-specific thrombosis and inflammation in COVID-19. J Thromb Haemost. 2021;19(12):3062–3072. doi:10.1111/jth.15532
   PubMed Web of Science ®Google Scholar
• Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med. 1987;166(4):1084–1097. doi:10.1084/jem.166.4.1084
   PubMed Web of Science ®Google Scholar
• Zhang N, Zhao YD, Wang XM. CXCL10 an important chemokine associated with cytokine storm in COVID-19 infected patients. Eur Rev Med Pharmacol Sci. 2020;24(13):7497–7505. doi:10.26355/eurrev_202007_21922
   PubMed Web of Science ®Google Scholar
• Lu Q, Zhu Z, Tan C, et al. Changes of serum IL-10, IL-1beta, IL-6, MCP-1, TNF-alpha, IP-10 and IL-4 in COVID-19 patients. Int J Clin Pract. 2021;75(9):e14462. doi:10.1111/ijcp.14462
   PubMed Web of Science ®Google Scholar
• Gudowska-Sawczuk M, Mroczko B. What is currently known about the role of CXCL10 in SARS-CoV-2 infection? Int J Mol Sci. 2022;23(7). doi:10.3390/ijms23073673
   Web of Science ®Google Scholar
• Chen Y, Wang J, Liu C, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26(1):97. doi:10.1186/s10020-020-00230-x
   PubMed Web of Science ®Google Scholar
• Kalinina O, Golovkin A, Zaikova E, et al. Cytokine storm signature in patients with moderate and severe COVID-19. Int J Mol Sci. 2022;23(16). doi:10.3390/ijms23168879
   Web of Science ®Google Scholar
• Heller EA, Liu E, Tager AM, et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation. 2006;113(19):2301–2312. doi:10.1161/CIRCULATIONAHA.105.605121
   PubMed Web of Science ®Google Scholar
• Koten K, Hirohata S, Miyoshi T, et al. Serum interferon-gamma-inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size. Clin Biochem. 2008;41(1–2):30–37. doi:10.1016/j.clinbiochem.2007.10.001
   PubMed Web of Science ®Google Scholar
• Wang X, Yue TL, Ohlstein EH, Sung CP, Feuerstein GZ. Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J Biol Chem. 1996;271(39):24286–24293. doi:10.1074/jbc.271.39.24286
   PubMed Web of Science ®Google Scholar
• Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med. 1993;177(6):1809–1814. doi:10.1084/jem.177.6.1809
   PubMed Web of Science ®Google Scholar
• Zabini D, Nagaraj C, Stacher E, et al. Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction. PLoS One. 2012;7(8):e43793. doi:10.1371/journal.pone.0043793
   PubMed Web of Science ®Google Scholar
• Lupieri A, Smirnova NF, Solinhac R, et al. Smooth muscle cells-derived CXCL10 prevents endothelial healing through PI3Kgamma-dependent T cells response. Cardiovasc Res. 2020;116(2):438–449. doi:10.1093/cvr/cvz122
   PubMed Web of Science ®Google Scholar